Your browser doesn't support javascript.
loading
Systematic review - Adjuvant radiotherapy of the vulva in primary vulvar cancer.
Proppe, L; Jaeger, A; Goy, Y; Petersen, C; Kruell, A; Prieske, K; Schmalfeldt, B; Mueller, V; Woelber, L.
Affiliation
  • Proppe L; Department of Gynecology and Gynecologic Oncology, University Medical Center Hamburg-Eppendorf, Germany.
  • Jaeger A; Department of Gynecology and Gynecologic Oncology, University Medical Center Hamburg-Eppendorf, Germany.
  • Goy Y; Department of Radiooncology, University Medical Center Hamburg-Eppendorf, Germany.
  • Petersen C; Department of Radiooncology, University Medical Center Hamburg-Eppendorf, Germany.
  • Kruell A; Department of Radiooncology, University Medical Center Hamburg-Eppendorf, Germany.
  • Prieske K; Department of Gynecology and Gynecologic Oncology, University Medical Center Hamburg-Eppendorf, Germany; Dysplasia Center at the Krankenhaus Jerusalem, Hamburg, Germany.
  • Schmalfeldt B; Department of Gynecology and Gynecologic Oncology, University Medical Center Hamburg-Eppendorf, Germany.
  • Mueller V; Department of Gynecology and Gynecologic Oncology, University Medical Center Hamburg-Eppendorf, Germany.
  • Woelber L; Department of Gynecology and Gynecologic Oncology, University Medical Center Hamburg-Eppendorf, Germany; Dysplasia Center at the Krankenhaus Jerusalem, Hamburg, Germany. Electronic address: l.woelber@uke.de.
Gynecol Oncol ; 190: 264-271, 2024 Sep 11.
Article in En | MEDLINE | ID: mdl-39265464
ABSTRACT

OBJECTIVE:

Adjuvant radiotherapy to the vulva in vulvar squamous cell carcinoma (VSCC) is frequently performed albeit strong evidence is lacking. This systematic review aims to summarize the current literature on this topic.

METHODS:

19 retrospective studies were included and analyzed, focusing on the primary outcome of local recurrence.

RESULTS:

The publications present conflicting results. While the benefit of adjuvant radiotherapy to the groins in case of node-positive VSCC is well established, the indication criteria and effectiveness of adjuvant radiotherapy to the vulva remain unclear. Based on the studies included in this review, the current evidence suggests that adjuvant radiotherapy to the vulva might not significantly reduce the risk of recurrence or only in certain subgroups.

CONCLUSION:

Most of the studies do not consider individual risk factors such as HPV status, resection margin, lymph node stage, grading and others. As a result, the comparability and reliability of these findings are limited. This review aims to highlight the need of further research addressing the risk stratification, considering both oncologic risk factors and adverse events.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Gynecol Oncol Year: 2024 Document type: Article Affiliation country: Germany Country of publication: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Gynecol Oncol Year: 2024 Document type: Article Affiliation country: Germany Country of publication: United States